Category - Developments

Developments

CymaBay reports positive seladelpar data in PBC

CymaBay Therapeutics (NASDAQ:CBAY) presented new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a type of liver disease that damages...

April 11, 2018

Developments

Arbutus and Roivant launch Genevant Sciences to develop RNA therapeutics

Arbutus Biopharma (NASDAQ:ABUS) and closely-held Roivant Sciences of Switzerland agreed to launch Genevant Sciences, a jointly-owned company focused on the discovery, development, and commercialization of a broad range...

April 11, 2018

Developments

BiondVax begins NIH-sponsored universal flu vaccine trial

BiondVax Pharmaceuticals (NASDAQ:BVXV) enrolled the first participant in a U.S. Phase 2 clinical trial of its universal flu vaccine candidate, M-001. The trial is sponsored by the U.S. National Institute of Allergy and...

April 11, 2018

Developments

CellAegis Devices begins U.S. pivotal trial of autoRIC device

Closely-held CellAegis Devices has enrolled the first patients in a U.S. pivotal trial of its autoRIC device, which automatically delivers remote ischemic conditioning (RIC) to provide a non-invasive, cardio-protective...

April 10, 2018

Developments

Ortho RTi posts positive Ortho-R data in rotator cuff repair

Ortho Regenerative Technologies (CSE:ORTH) reported positive preliminary MRI outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from...

April 2, 2018

Developments

BioLight completes first stage of sale of IOPtima

BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the first stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the first...

March 29, 2018

Developments

Molteni acquires Titan Pharma’s European Probuphine IP

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...

March 22, 2018

Developments

Vital Therapies completes enrollment in VTL-308 pivotal trial

Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...

March 22, 2018

Developments

Scientus Pharma gains media awareneness

A Canadian Press piece appearing in several newspapers and broadcast news reports features closely-held Scientus Pharma and other companies as they look beyond legalization of recreational cannabis this summer to...

March 16, 2018

Developments

Ortho RTi gets European patent allowance protecting Ortho-R technology

Ortho Regenerative Technologies (CSE:ORTH) has received a notice of allowance from the European Patent Office that when issued, will provide intellectual property protection for the composition of matter of its Ortho-R...

March 8, 2018

Category - Developments

CymaBay reports positive seladelpar data in PBC

Arbutus and Roivant launch Genevant Sciences to develop RNA therapeutics

BiondVax begins NIH-sponsored universal flu vaccine trial

CellAegis Devices begins U.S. pivotal trial of autoRIC device

Ortho RTi posts positive Ortho-R data in rotator cuff repair

BioLight completes first stage of sale of IOPtima

Molteni acquires Titan Pharma’s European Probuphine IP

Vital Therapies completes enrollment in VTL-308 pivotal trial

Scientus Pharma gains media awareneness

Ortho RTi gets European patent allowance protecting Ortho-R technology

General

More